Survival outcomes of patients after first relapse of BCP-ALL by NT5C2 mutation status. (A) Event-free survival (EFS). (B) Overall survival (OS). (C) Competing risk analysis of cumulative incidence of relapse (CIR) at 10 years. (D) Competing risk analysis of cumulative incidence of treatment related death (CID) at 10 years. cens, censored.